FDA Approves First Factor XIa Inhibitor, Sunharbo, for Secondary Stroke Prevention
The U.S. Food and Drug Administration has approved Sunharbo as the first factor XIa inhibitor to help prevent secondary strokes when combined with antiplatelet therapy.
🧠AI AnalysisPhoto: Medical Xpress
Key points
- FDA approved Sunharbo (asundexian) 50 mg for secondary stroke prevention.
- Phase 3 OCEANIC-STROKE study showed a 26% reduction in ischemic stroke risk.
- The therapy carries increased bleeding risks for patients over 75 and during early treatment.
The U.S. Food and Drug Administration (FDA) has granted approval to Sunharbo 50 mg tablets (asundexian) for use alongside antiplatelet therapy to lower stroke risks in adults who have experienced a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). This regulatory decision marks the introduction of the first factor XIa inhibitor approved for this specific clinical application.
Regulatory authorization stems from the phase 3 OCEANIC-STROKE trial, which evaluated 12,327 adult participants. Individuals were randomized to receive either Sunharbo or a placebo within 72 hours of symptom onset. Findings indicate that a once-daily 50 mg dose of Sunharbo, paired with antiplatelet medication, reduced ischemic stroke risk by 26% compared to the placebo group over a median treatment duration of 14.2 months.
While overall major bleeding rates remained comparable between the cohorts, researchers noted an increased bleeding risk among patients over the age of 75 and throughout the initial 90 days of treatment. Gastrointestinal bleeding was more frequent in the medication group, and diarrhea emerged as the most common adverse reaction, affecting 3% or more of treated patients. Additionally, the therapy is not recommended for individuals with moderate or severe hepatic impairment, those taking strong CYP3A4 and P-gp inducers, or patients with atrial fibrillation.
What to know: Sunharbo is a new prescription option for secondary stroke prevention in specific adult populations, but it carries notable bleeding risks in certain demographic groups. Always consult a qualified healthcare provider for personalized medical decisions and treatment strategies.
Source Medical Xpress — medicalxpress.com/news/2026-11-fda-factor-xia-inhibitor-secondary.html ↗
Read next
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …